Skip to content
Abierto

Award notice

PREVENT IDIQ MATO RFP

75N91024D00003

National Institutes of Health, NIH NCI. Research and Development in Biotechnology (except Nanobiotechnology).

Awarded

The Institute for Cancer Research

$149,995,000.00 on the award notice, January 24, 2024, contract 75N91024D00003

Description

As published on SAM.gov.

PREVENT EFFICACY Pool: This contract supports the PREVENT Cancer Preclinical Drug Development Program, which provides a structured approach to drug and vaccine development, from discovery to the clinic. This contract is a part of a multiple-award Indefinite Delivery Indefinite Quantity (IDIQ) pool to procure services related to Preclinical Efficacy and Intermediate Endpoint Biomarkers, which is also referred to as the Efficacy Pool.

The contract, on USAspending

Federal procurement data the awarding office reported to FPDS, matched to this solicitation by its number.

UEI
FF1XVJMDYVR1
CAGE
1RAF4
Vendor location
Philadelphia, PA
Contract
75N91024D00003
Obligated
$0.00, potential $149,995,000
Actions
5 between January 24, 2024 and June 29, 2026
Competition
Full and Open Competition, 9 offers received
Set-aside reported
No Set Aside Used.
Described as
Preclinical Efficacy & Intermediate Endpoint Biomarkers IDIQ Contract in Support of the Prevent Cancer Preclinical Drug Development Program
Match
award number 75N91024D00003 equals the contract number; same awarding office 75N910 (high confidence)

Publications

Every notice SAM.gov issued under this solicitation number, oldest first. Each is a separate record on SAM.

  1. January 29, 2024

    Award notice, originally solicitation

    Awarded to THE INSTITUTE FOR CANCER RESEARCH Philadelphia for $149,995,000. SAM.gov, notice 809ccf25834e4026b9dab0f70004c2af

  2. January 31, 2024

    Award notice

    Awarded to THE INSTITUTE FOR CANCER RESEARCH Philadelphia for $149,995,000. SAM.gov, notice 66b245669a754e81b79d00f02262ad1b

Points of contact